Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance.
about
The measurement of protein synthesis for assessing proteostasis in studies of slowed agingmTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and agingLifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycinTemsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular PhenotypeMolecular mechanisms for mitochondrial adaptation to exercise training in skeletal muscle.Latest progress in tyrosine kinase inhibitorsTarget of rapamycin signalling mediates the lifespan-extending effects of dietary restriction by essential amino acid alteration.From rapalogs to anti-aging formula.TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.Selective anti-cancer agents as anti-aging drugsGerosuppression in confluent cells.Genetically diverse mice are novel and valuable models of age-associated susceptibility to Mycobacterium tuberculosis.Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat dietTumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.Comparison of rapamycin schedules in mice on high-fat diet.Rejuvenating immunity: "anti-aging drug today" eight years later.Koschei the immortal and anti-aging drugsMetabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus)Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).Rapamycin Versus Intermittent Feeding: Dissociable Effects on Physiological and Behavioral Outcomes When Initiated Early and Late in Life.Aging is not programmed: genetic pseudo-program is a shadow of developmental growth.Gerosuppression by pan-mTOR inhibitors.Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition.Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium.M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.Energetic interventions for healthspan and resiliency with aging.Immunosuppressants in cancer prevention and therapyTOR-inhibitors as gero-suppressors.Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J-Leprdb mice.Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome.
P2860
Q27016145-4724272A-F6C2-4C06-A9DE-002E3E6A243DQ28081442-30CFEAE5-9D66-42E8-9E34-A4D75186D2F6Q28307873-0CC9F881-0794-4046-B429-6C706BAB422DQ28468499-33ACAC09-3A08-4BA8-9FB4-5AEBDBF258FBQ30278688-8BBA4652-F007-48A7-8060-085D62563BC8Q33576849-107B747D-4FCA-4F97-B571-3ADFF34E4806Q33801201-5B73EBD5-5CCE-4A63-99DE-733785611300Q33829205-DEF02036-50AD-4C4F-8E79-87BD9A39DC72Q34391710-CA9006DF-30FC-45D3-9AF7-06D539552DEDQ34392470-EB24A9CA-7C9F-4C7B-B5EA-8D274741FEC7Q34982499-4D34AFC9-AB66-4F27-93E9-D7A8D068B894Q34986125-96FE5FE1-47BE-408E-ADCD-0C094991CFAAQ35080619-70004D21-667A-43EA-B13C-F21483695F5FQ35149607-BA21523F-CE6D-40B7-B740-415BA5FF91F1Q36189078-264DE8F8-E157-4317-B8E5-E4FD20BB8B2EQ36260537-D30B6E01-1E58-4E09-AA97-A9102C03036FQ36292001-2BC0C375-7AB6-4C52-9A81-C533D04D9324Q36411111-47B06DB8-3392-44A1-A397-EDA42E9FADA6Q36414149-531047A0-2FBB-4EE3-A1C9-4A4D601338E4Q37000448-25B559FC-D46E-4E6A-ACA8-DDB3705995A9Q37525814-E87E698E-842E-4E0D-A0FD-B916D0B87F7CQ37610218-AB181AD6-E142-4EFD-9D86-0F33FCD75310Q38454084-BA66EAC2-B797-4D25-BC80-8661D3AB5D6BQ38997125-CE1DF6E7-F1E6-4E2E-8F3E-446D0F0E417AQ39027265-13EBFFBD-EA6C-41B2-9ADC-95BCC9336526Q39291992-3726F26D-AA2E-473B-A84E-23475AE6983FQ42505783-30CB22C9-3FFF-4DF6-B866-05211D67F7DEQ43089284-02CF8956-8BFF-4F0A-9E6F-38652D7E2E13Q47548477-090670A0-1B7E-41BD-9196-E773A320B348Q50426370-9B06F71B-C1F7-4A0B-A94F-3B0AFE9D8ACD
P2860
Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rapamycin doses sufficient to ...... hondrial content or endurance.
@en
Rapamycin doses sufficient to ...... hondrial content or endurance.
@nl
type
label
Rapamycin doses sufficient to ...... hondrial content or endurance.
@en
Rapamycin doses sufficient to ...... hondrial content or endurance.
@nl
prefLabel
Rapamycin doses sufficient to ...... hondrial content or endurance.
@en
Rapamycin doses sufficient to ...... hondrial content or endurance.
@nl
P2093
P2860
P356
P1433
P1476
Rapamycin doses sufficient to ...... hondrial content or endurance.
@en
P2093
Anne L Widlund
Carrie A Sims
David E Harrison
David M Sabatini
Dudley W Lamming
James G Davis
Joseph A Baur
Yuxia Guan
P2860
P304
P356
10.18632/AGING.100576
P577
2013-07-01T00:00:00Z